Recent UK reports and an FDA label change suggest older users of GLP‑1 weight‑loss drugs may face higher safety concerns.
The surge in prescriptions for GLP-1 receptor agonists such as Wegovy, Mounjaro and semaglutide has sparked a wave of weight-loss success stories across Britain. Yet a deep dive into the Medicines and Healthcare products Regulatory Agency’s Yellow Card database reveals a stark age-related pattern in reported deaths.
While people in their 40s receive the bulk of private prescriptions, the fatality count is heavily skewed toward those in their 60s.
UK mortality data highlights a mid-life discrepancy
According to the latest figures, 311 deaths have been linked to GLP-1 drugs, up 44 % since August.
When the numbers are split by age, individuals aged 60-69 account for 88 reported deaths, and those 70-79 add another 38. In contrast, the 30-39 cohort records just 20 deaths, and the 40-49 group another 20.
Despite the fact that 57 % of private GLP-1 prescriptions go to 30-49-year-olds, this group represents only 12 % of the reported fatalities. People aged 50-69, who make up roughly one-third of private prescriptions, are responsible for nearly half of the deaths recorded.
The disparity raises questions about physiological vulnerability. Older patients often carry multiple chronic conditions and take several concomitant medications, factors that can amplify the risk of dehydration, electrolyte imbalance, gallbladder disease or acute pancreatitis: complications already associated with the drug class. A 19-year-old student’s death in London, attributed to low-blood-sugar-induced arrhythmia after taking tirzepatide, underscores that severe outcomes can occur at any age, though they appear more frequent among the middle-aged and elderly.
FDA issues class-wide warning for optic-nerve damage
On 9 November 2026, the U.S. Food and Drug Administration released a Drug Safety Communication requiring every manufacturer of GLP-1 agonists to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION). The label update covers twelve products, ranging from semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) to the oral molecule orforglipron (Foundayo). NAION is a rare vascular event that causes sudden, painless loss of vision in one eye, potentially permanent.
The FDA’s decision follows a series of observational studies. A 2024 JAMA Ophthalmology paper reported a hazard ratio of 4.28 for NAION among semaglutide users compared with non-GLP-1 diabetics, while later large-scale analyses observed more modest increases (approximately 6.4 cases per 100 000 person-years versus 3.8 with placebo). The agency’s meta-analysis of 126 randomised trials identified 15 probable NAION events among over 78 000 GLP-1 recipients, prompting a precautionary, class-wide approach.
Clinicians are now advised to screen patients for established NAION risk factors (hypertension, diabetes, sleep apnoea, smoking, anaemia and kidney disease) before initiating therapy. If optic-nerve symptoms arise, immediate referral to an ophthalmologist and consideration of drug discontinuation are recommended. The FDA also encourages reporting of any NAION cases through MedWatch.
Balancing benefits and risks for older adults
Despite the highlighted concerns, most GLP-1 users experience no serious adverse events and may enjoy added benefits such as improved glycaemic control, reduced cardiovascular risk, and possible protection against dementia and certain cancers. Nevertheless, the combination of age-related comorbidities and rapid weight loss, which can erode muscle and bone density, makes careful patient selection essential. Studies have linked substantial weight loss in middle-aged adults to a 39 % rise in fracture risk at key skeletal sites.
Experts stress that the data do not prove causality; rather, they signal a need for heightened vigilance when prescribing to individuals over 50. Ongoing monitoring, patient education about dehydration, electrolyte balance and visual changes, and individualized risk-benefit assessments remain the cornerstone of safe GLP-1 therapy.
